KOSDAQ-listed Seegene said on the 25th that, on a consolidation basis, its operating profit for last year came to 34.6 billion won, turning to a profit from a year earlier (an operating loss of 16.5 billion won), based on preliminary figures. Revenue was 474.2 billion won, up 14.5% from a year earlier. Net profit returned to the black at 48.4 billion won.
Fourth-quarter operating profit was 6.9 billion won, turning to a profit from the same period a year earlier (an operating loss of 6.2 billion won). Revenue and net profit for the quarter were 130.6 billion won and 16.6 billion won, respectively.
Seegene said fourth-quarter non-respiratory product lines posted solid growth while respiratory product lines also showed signs of recovery. Sales of non-respiratory syndromic product lines increased 24.4% from a year earlier, and for respiratory product lines, demand recovered in the fourth quarter, leading to overall improvement.
The company added that it is maintaining a solid sales base in the European market while continuously seeking expansion opportunities in major global markets.
Seegene emphasized that it is pushing to strengthen its diagnostic operating system by linking STAgora™—which consolidates and provides global PCR test result statistical data to help understand disease trends in real time—and CURECA™, a fully unmanned automation system that automates the entire PCR testing process.
The company plans to improve laboratory operational efficiency through CURECA and to expand the use of PCR test results by analyzing and sharing accumulated statistical data from STAgora in real time.
Seegene plans to unveil the current status and future direction of STAgora and CURECA on the global stage, including at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in April and the Association for Diagnostics & Laboratory Medicine (ADLM) in July.
Kim Jeong-yong, Seegene's head of financial management, said, "This year, using major global conferences as momentum, we plan to share a roadmap that will change the paradigm of future testing, such as STAgora and CURECA, and to gradually improve the technology and scope of application based on on-site feedback and operating data."